CDIO Stock Forecast: Cardio Diagnostics Holdings, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 20 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Cardio Diagnostics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (74): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (6): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CDIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CDIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Aug 2024 | Benchmark | Reiterates | Speculative Buy | $2.00 |
| 6 June 2024 | Benchmark | Maintains | Speculative Buy | — |
| 19 Apr 2024 | Benchmark | Maintains | Speculative Buy | — |
| 15 June 2023 | Benchmark | Reiterates | Speculative Buy | — |
| 22 May 2023 | Northland Capital Markets | Initiates | Outperform | — |
| 18 Apr 2023 | Benchmark | Reiterates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
CDIO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CDIO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Cardio Diagnostics Holdings, Inc. returned −35.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CDIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 311.8×
- Price / book
- 0.8×
- EV / EBITDA
- —
Cheaper than 2% of US stocks
Cheaper than 77% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −93.5%
- Return on assets
- −54.4%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cardio Diagnostics Holdings, Inc. has a market value of $4.7M and an enterprise value of $1.0M.
Revenue in the twelve months to 30 June 2026: $14K. The latest quarter shrank 28.3% year on year.
Net income over the same four quarters: −$6.5M, a −44771.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$6.1M.
Cardio Diagnostics Holdings, Inc. employs 15 people — $963.3 of revenue per employee.
Data provided by Twelve Data
CDIO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CDIO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Cardio Diagnostics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CDIO
How does Ticker Nerd's model rank CDIO?
As at 21 Nov 2026, Cardio Diagnostics Holdings, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (74 of 100).
What is the CDIO stock forecast for 2030?
No analyst covering Cardio Diagnostics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDIO are extrapolating price history, which says nothing about the business.
How has CDIO stock performed over the past year?
Cardio Diagnostics Holdings, Inc. returned -35.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Cardio Diagnostics Holdings, Inc. do?
Cardio Diagnostics Holdings, Inc. is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular disease. The company’s current offerings include blood-based diagnostics for coronary heart disease risk assessment and early detection, supported by AI-driven analysis of genetic and epigenetic biomarkers.
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular disease. The company’s current offerings include blood-based diagnostics for coronary heart disease risk assessment and early detection, supported by AI-driven analysis of genetic and epigenetic biomarkers. Cardio Diagnostics also provides tools and platforms that help clinicians interpret cardiovascular risk and support research and development use in biopharmaceutical and medical settings. Its products are designed to improve the assessment, detection, and management of cardiovascular conditions such as coronary heart disease and related comorbidities through more precise clinical insights. Based in Chicago, Illinois, Cardio Diagnostics Holdings serves the growing market for advanced cardiovascular diagnostics and precision medicine.
CEO Dr. Meeshanthini V. Dogan Ph.D. · 15 employees · United States · https://cdio.ai